Needle-less to say, it’s effective! Eli Lilly’s experimental GLP-1 pill caused participants in a late-stage trial to shed an average of 10.5% of their body weight — nearly 23 pounds — over 16 months, ...

Wall Street investment firm Jefferies Financial Group (JEF) is forecasting more than $10 billion in annual sales from Eli Lilly’s (LLY) new weight-loss pill that’s expected to hit the market in 2026.

This could really move the needle in the GLP-1 weight loss market. Semaglutide, the active ingredient in Ozempic and Wegovy, is injected into the fatty tissue just under the skin of the stomach, thigh ...

Eli Lilly’s experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.

An effective weight-loss pill to rival injectable drugs like Ozempic and Zepbound might be on the horizon, clinical trial results show. An experimental GLP-1 pill called orforglipron promoted ...